ParkerVision Patent Infringement Trial Against MediaTek Postponed

The postponement of the patent infringement trial between ParkerVision and MediaTek marks the latest chapter in a protracted legal saga that has significant implications for the global semiconductor industry. ParkerVision, a Florida-based technology firm that has transitioned into a specialized patent assertion entity, alleges that MediaTek’s wireless communication chips infringe upon its foundational patents related to radio frequency (RF) down-conversion and up-conversion. These technologies are essential for modern mobile devices, enabling the efficient translation of high-frequency signals into data that can be processed by smartphone processors. The delay, while procedural in nature, extends the uncertainty surrounding a case that could result in substantial royalty payments or a significant settlement for ParkerVision.

Industry context reveals that ParkerVision has a long history of aggressive litigation against the world's largest chip manufacturers, including Qualcomm, Intel, and Apple. The core of their legal strategy rests on 'energy transfer' technology, which they claim revolutionized RF receiver design. While ParkerVision has faced setbacks in past trials—most notably a reversed $173 million verdict against Qualcomm in 2014—the company has remained persistent, often securing litigation funding to sustain these high-cost legal battles. For MediaTek, the world’s leading vendor of smartphone SoCs by volume, the trial represents a defense of its core product architecture. A loss or a high-value settlement could set a precedent that affects other major players in the RF front-end market.

“

While ParkerVision has faced setbacks in past trials—most notably a reversed $173 million verdict against Qualcomm in 2014—the company has remained persistent, often securing litigation funding to sustain these high-cost legal battles.

Recent financial filings from ParkerVision suggest the company is bracing for a long-term engagement. On March 13, 2026, just days before the scheduled trial, ParkerVision entered into a material definitive agreement involving the unregistered sale of equity securities. This move is frequently interpreted by analysts as a mechanism to bolster cash reserves to cover ongoing legal fees and operational costs during trial delays. The company's stock (PRKR) remains highly volatile, often reacting sharply to court rulings, discovery phases, and scheduling changes, as its valuation is almost entirely tied to the potential outcomes of its intellectual property portfolio.